

Dr. James Cardelli
603 Avignon Lane
Shreveport, LA 71115
(318) 564-8976

RECEIVED
2015 DEC 14 AM 9:19

December 9, 2015

VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED

Ms. Cathleen Allen
Executive Counsel
Louisiana Ethics Administration Program
P.O. Box 4368
Baton Rouge, LA 70821

Dear Ms. Allen:


My name is Dr. James A. Cardelli and I am currently a Professor at Louisiana State University in Shreveport. I will be retiring from LSUHSC effective December 31, 2015, and will be launching a start-up business, which will focus on drug repurposing and development. As part of the business plan, I would like to continue interaction in a collaborative fashion with the Innovative Louisiana Experimental Therapeutics Program (INLET) which I had directed for four years. Since the INLET program is affiliated with LSUHSC, my attorney, Allison Jones, has recommended I send you a letter asking for your advice on if this interaction and if it is in violation of any State Ethics Board rulings. I am aware that I cannot receive compensation from LSUHSC or their affiliates for a period of two years following separation. I list below the types of interactions I would like to continue between LSUHSC/INLET and my proposed company:

- As part of my business plan I need to license back some of the technology I developed while at LSUHSC, some of which has been filed as provisional patent applications. Intellectual property ownership will be critical for success of my company.
- I would also like my company to set up a collaborative interaction with INLET that will involve doing research to aid the development of drugs INLET has currently identified and would hopefully advance towards clinical trials. Neither I nor my proposed company would receive no compensation for this business interaction, and would, in fact, either pay for this service or negotiate with the OSPTT for an equity stake in the company. Payment for services will be in the form of money being raised by the company, a federal grant or payment in kind.
- Part of the proposed company's five-year plan would be to advance these compounds to the point where the technology or products will potentially be licensed out to a larger pharmaceutical company. Both the company and LSUHSC will receive compensation for this, so we perceive this interaction as being mutually beneficial.
- Finally, as former Director of INLET and previous principal investigator on sponsored research agreements with K94 Discoveries (President Ross Barrett), I would like to

continue to consult with the INLET team to ensure the goals of the newest SRA are met in a timely manner. I will seek no compensation from the LSUHSC or INLET for this service.

I thank you for your time and look forward to your opinion regarding any potential violation of the State Ethics laws. It is my sincere desire to be compliance with the same and I, accordingly, request this advisory opinion. If you have any additional questions please do not hesitate to contact me at 318-564-8976 or jcarde@gmail.com.

Sincerely,

A handwritten signature in cursive script that reads "James Cardelli".

James A. Cardelli, PhD
Professor of Microbiology and Immunology LSU Health Sciences Center
Director of the Innovative North Louisiana Experimental Therapeutics Program

cc: Allison Jones, Attorney